OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Navigating Evolving Therapy Choice in Multiple Myeloma

home / peer-exchange / mm-evolving-therapy-choice
Advertisement
Smoldering Myeloma: Treatment and Risk Stratification

EP. 1: Smoldering Myeloma: Treatment and Risk Stratification

June 26th 2019
Clinical Trials' Impact on Smoldering Myeloma Management

EP. 2: Clinical Trials' Impact on Smoldering Myeloma Management

June 26th 2019
Treating Myeloma: Newly Diagnosed Transplant-Eligible Patients

EP. 3: Treating Myeloma: Newly Diagnosed Transplant-Eligible Patients

June 26th 2019
Trial Data in Newly Diagnosed Transplant-Eligible Myeloma

EP. 4: Trial Data in Newly Diagnosed Transplant-Eligible Myeloma

June 26th 2019
Newly Diagnosed Transplant-Eligible Myeloma: The Role of MRD

EP. 5: Newly Diagnosed Transplant-Eligible Myeloma: The Role of MRD

June 26th 2019
Newly Diagnosed Myeloma: Transplant Ineligibility and Treatment

EP. 6: Newly Diagnosed Myeloma: Transplant Ineligibility and Treatment

June 26th 2019
Advertisement
Emerging Therapies for Relapsed/Refractory Multiple Myeloma

EP. 7: Emerging Therapies for Relapsed/Refractory Multiple Myeloma

June 26th 2019
Subcutaneous Daratumumab in R/R Myeloma: The COLUMBA Trial

EP. 8: Subcutaneous Daratumumab in R/R Myeloma: The COLUMBA Trial

June 26th 2019
Venetoclax in Relapsed/Refractory Myeloma: The BELLINI Trial

EP. 9: Venetoclax in Relapsed/Refractory Myeloma: The BELLINI Trial

June 26th 2019
Considering Oral Selinexor for Relapsed/Refractory Myeloma

EP. 10: Considering Oral Selinexor for Relapsed/Refractory Myeloma

June 26th 2019
Establishing the Potential of AMG 420 in R/R Multiple Myeloma

EP. 11: Establishing the Potential of AMG 420 in R/R Multiple Myeloma

June 26th 2019
Considering Other CAR T-Cell Strategies in R/R Myeloma

EP. 12: Considering Other CAR T-Cell Strategies in R/R Myeloma

June 26th 2019
Advertisement
Improving the Future Management of Multiple Myeloma

EP. 13: Improving the Future Management of Multiple Myeloma

June 26th 2019

Latest Conference Coverage

Dr Deek on the Investigation of Immune Cell Infiltration in MIBC

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

Dr Hoppe on the Rationale for the CheckMate 744 Trial in Hodgkin Lymphoma

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact